ABT-263 (Navitoclax) 化学構造
分子量: 974.61

高品質保証

文献中の引用(36)

カスタマーフィードバック(13)

Quality Control & MSDS

製品説明

  • Compare Bcl-2 Inhibitors
    Bcl-2製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 ABT-263(Navitoclax)は、 Bcl-xLBcl-2Bcl-w の強力な阻害剤で、Kiがそれぞれ ≤ 0.5 nM、≤1 nM 、≤ 1 nMです。
ターゲット

Bcl-xL

Bcl-2

Bcl-w

IC50

≤ 0.5 nM (Ki)

≤1 nM (Ki)

≤ 1 nM (Ki)[1]

In vitro試験 ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cell MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jqd2lEPTB;MD6wNFY3QSEQvF2= NHKx[GtUSU6JRWK=
MV-4-11 M1TxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX1TWM2OD1yLkCxOVg3KM7:TR?= M3\ZUXNCVkeHUh?=
NKM-1 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXZT|VKSzVyPUCuNFE3QTlizszN NVrJcmtjW0GQR1XS
ML-2 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW0SY0{UUN3ME2wMlAyQTh|IN88US=> NXTzeY5MW0GQR1XS
BV-173 NV7HdGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMEKzNVQh|ryP M2Cxb3NCVkeHUh?=
RS4-11 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq5V5lKSzVyPUCuNFI2QDdizszN M{XzRXNCVkeHUh?=
HL-60 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jqNWlEPTB;MD6wNlkxQCEQvF2= NXzy[mtuW0GQR1XS
KY821 NF;Mb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrNZmFKSzVyPUCuNFI6PzVizszN NX:0b5ZJW0GQR1XS
ECC10 NXvTc4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[yOmI3UUN3ME2wMlA{Pzl{IN88US=> NWrhZlZCW0GQR1XS
NCI-H720 M{PyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTZVG03UUN3ME2wMlA1ODFzIN88US=> NH;zSGlUSU6JRWK=
QIMR-WIL M2LmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2bmlEPTB;MD6wOFI5PyEQvF2= MWrTRW5ITVJ?
KG-1 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTvV5dCUUN3ME2wMlA1PDh4IN88US=> NVXndJluW0GQR1XS
TGW NWG0OYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfrTWM2OD1yLkC0OlM{KM7:TR?= Moi5V2FPT0WU
ATN-1 NGjzdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13pbmlEPTB;MD6wOFc{OyEQvF2= NVzkbXlmW0GQR1XS
RH-18 MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmwW|VKSzVyPUCuNFYxPDhizszN MnXPV2FPT0WU
EW-18 NWq4cZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvvZZFEUUN3ME2wMlA3QDRzIN88US=> M{n5dXNCVkeHUh?=
NB17 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEexNlQh|ryP MnfHV2FPT0WU
SK-NEP-1 NXrKblluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H2[GlEPTB;MD6wO|IyOyEQvF2= MYrTRW5ITVJ?
P12-ICHIKAWA NHfLNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHuepdKSzVyPUCuNFc4PzhizszN Mk\ZV2FPT0WU
KARPAS-45 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMEe4NVUh|ryP M3;Ve3NCVkeHUh?=
EW-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq2XY9KSzVyPUCuNFgxPTNizszN MlnHV2FPT0WU
NB13 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXuTWM2OD1yLkC4NlA{KM7:TR?= NUDlcJNVW0GQR1XS
NCI-H209 M2DVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfmN4VTUUN3ME2wMlA5PzB2IN88US=> MnW5V2FPT0WU
NCI-H1092 NITEb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMUCyO|Uh|ryP MXzTRW5ITVJ?
NH-12 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMUC3OFQh|ryP NFXOZpBUSU6JRWK=
697 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHHfpI4UUN3ME2wMlExQDN7IN88US=> NGLWbXdUSU6JRWK=
KE-37 NVrsOnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDCOGhlUUN3ME2wMlEyOzdizszN NWX2dlVoW0GQR1XS
MOLT-4 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETiendKSzVyPUCuNVUyPjlizszN NGTkb2ZUSU6JRWK=
CHP-134 NIPlW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMU[zNFYh|ryP NWXEbY5KW0GQR1XS
D-283MED M3LhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMUe2PFYh|ryP NGf0emdUSU6JRWK=
LU-135 NIDZbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUi1OVIh|ryP NHXUWm9USU6JRWK=
LU-134-A NFi2VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nQO2lEPTB;MD6xPFY4OSEQvF2= MV7TRW5ITVJ?
EM-2 NUXUW2ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tn[2lEPTB;MD6xPVkyQCEQvF2= M2XhNHNCVkeHUh?=
LU-139 M{n0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzrXmZKSzVyPUCuNlA1QThizszN NFvuVYNUSU6JRWK=
ALL-PO Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[w[IFMUUN3ME2wMlIyQTh6IN88US=> MVHTRW5ITVJ?
NB12 NFPueIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\qdJpKSzVyPUCuNlMyOTVizszN MV7TRW5ITVJ?
KP-N-YN M2r4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[x[ZdYUUN3ME2wMlI{PTd|IN88US=> NWDjW3NxW0GQR1XS
BEN M4\HS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfWTWM2OD1yLkKzPVY5KM7:TR?= M4fUZXNCVkeHUh?=
HCC1569 NUHFUotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkWxNFYh|ryP NUjrdnRxW0GQR1XS
HuO9 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxWJhTUUN3ME2wMlI3PzF3IN88US=> MVrTRW5ITVJ?
WM-115 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKxTWM2OD1yLkK3O|M5KM7:TR?= MmOyV2FPT0WU
CCRF-CEM NXLZ[JFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfWWFJKSzVyPUCuN|M2OjlizszN NFXabpJUSU6JRWK=
IST-SL1 NX;qXVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLYTWM2OD1yLkO1N|Q{KM7:TR?= M4TzNHNCVkeHUh?=
BE-13 NG\YOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki3TWM2OD1yLkO2OFU6KM7:TR?= MVnTRW5ITVJ?
COR-L88 M3PJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfoeo9KSzVyPUCuN|Y2PCEQvF2= MYLTRW5ITVJ?
DOHH-2 NGfNdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwNEGwNlMh|ryP NGT6XVRUSU6JRWK=
A704 M{[2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDzVpVKSzVyPUCuOFI3PyEQvF2= MVjTRW5ITVJ?
KNS-81-FD NYfl[IFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNESwNVch|ryP M4e2ZnNCVkeHUh?=
RPMI-8226 NETTSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNEW2OVIh|ryP MmC1V2FPT0WU
TGBC24TKB NHLTcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y1e2lEPTB;MD60OVc4QCEQvF2= Mm\kV2FPT0WU
NCI-H1304 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnVS49KSzVyPUCuOFYyPTdizszN MlLmV2FPT0WU
MOLT-13 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO5TmdTUUN3ME2wMlQ3PjF|IN88US=> M2T5UXNCVkeHUh?=
EW-22 NGSwVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi2S5V6UUN3ME2wMlQ3PjdzIN88US=> M2nhXnNCVkeHUh?=
MS-1 M1jhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPSfG9uUUN3ME2wMlQ3QTN|IN88US=> MX\TRW5ITVJ?
RMG-I MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXHWnNDUUN3ME2wMlQ6PDZ2IN88US=> Ml3ZV2FPT0WU
NTERA-S-cl-D1 NXzZb2VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNUCwNVkh|ryP NFO4VoFUSU6JRWK=
NCI-H1048 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID4OmVKSzVyPUCuOVA6PTNizszN MoLsV2FPT0WU
SW1417 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;sNYZwUUN3ME2wMlU2PDN6IN88US=> NIjwNphUSU6JRWK=
DB M{LWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\VdJJ7UUN3ME2wMlU4ODhizszN M13WeXNCVkeHUh?=
MEG-01 NUG2UIJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:wTWM2OD1yLkW4N|Ih|ryP MnHvV2FPT0WU
EW-13 M3Pkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;lUIJKSzVyPUCuOVg{PDFizszN NUTRfXJvW0GQR1XS
LAMA-84 NV76XHZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[2V2lEPTB;MD61PVIxPyEQvF2= NXvL[oNLW0GQR1XS
J-RT3-T3-5 NHjlZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXRTWM2OD1yLk[wPFA5KM7:TR?= NHu5TVdUSU6JRWK=
MOLT-16 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jyNWlEPTB;MD62OVI3PCEQvF2= MnTsV2FPT0WU
DU-4475 NFv0NZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwNkW0Nlch|ryP MlW1V2FPT0WU
HAL-01 NEL6[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT0TWM2OD1yLkeyOVQ6KM7:TR?= Moe4V2FPT0WU
RD MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13uSGlEPTB;MD63OVg6QSEQvF2= MYrTRW5ITVJ?
OAW-28 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu1bldKSzVyPUCuO|g{PyEQvF2= MnqxV2FPT0WU
HCC38 NXzYZYtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r5RmlEPTB;MD64NFE6KM7:TR?= Mn7KV2FPT0WU
NMC-G1 NWXSZYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vBcWlEPTB;MD64NVEzOSEQvF2= M1XzUHNCVkeHUh?=
EW-16 M1uyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXnb3dKSzVyPUCuPFE{OjhizszN NGOyNZJUSU6JRWK=
DU-145 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfBXGpRUUN3ME2wMlg6QTJ|IN88US=> NX74fpJrW0GQR1XS
HPAF-II MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLITWM2OD1yLkmyOlI5KM7:TR?= M4DoW3NCVkeHUh?=
A427 NV3BO2JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnMTWM2OD1yLkmzNFIzKM7:TR?= M{HJOHNCVkeHUh?=
PA-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3TTWM2OD1yLkm1OlQzKM7:TR?= MnG4V2FPT0WU
OAW-42 M3fNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K0cWlEPTB;MD65OlE1PiEQvF2= MnLGV2FPT0WU
L-428 NX72OXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwMEGyOUDPxE1? MWDTRW5ITVJ?
COLO-824 M{jG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMEG3NFgh|ryP MoCzV2FPT0WU
P30-OHK M3T1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37aW2lEPTB;MT6wOFY5QCEQvF2= MV;TRW5ITVJ?
NCI-H2170 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP1TlRlUUN3ME2xMlA3OjNizszN M3r3[XNCVkeHUh?=
HCC2998 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXPUZBmUUN3ME2xMlA4OTN3IN88US=> MVPTRW5ITVJ?
NB14 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwMUO3OFgh|ryP MYnTRW5ITVJ?
TGBC1TKB M1K4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;XPWlEPTB;MT6xOFE2OiEQvF2= NI\Rb|dUSU6JRWK=
KP-N-YS MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DxWGlEPTB;MT6xOlI{PiEQvF2= NUe5V5RDW0GQR1XS
CAL-120 NFHRNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwMU[0Nlkh|ryP NVPzd5U{W0GQR1XS
SBC-1 M1vYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSyTWM2OD1zLkG5NFU{KM7:TR?= M3O5cnNCVkeHUh?=
C32 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7EWXdKSzVyPUGuNVkxQDhizszN MXLTRW5ITVJ?
HCC2157 NGrnVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHNOGxKSzVyPUGuNVk1QTRizszN MUDTRW5ITVJ?
COLO-792 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rwXWlEPTB;MT6yNFA4OSEQvF2= MU\TRW5ITVJ?
ES7 NIHQWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTxWYJKSzVyPUGuNlc6PTFizszN NI\KSZRUSU6JRWK=
HEL NUnBNIFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwM{GwNlkh|ryP NV\RTWpCW0GQR1XS
ES4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\pTWM2OD1zLkO0PVk5KM7:TR?= M4K5bnNCVkeHUh?=
NCI-SNU-1 M3nFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrrT3czUUN3ME2xMlM3PTV3IN88US=> M{PqS3NCVkeHUh?=
MDA-MB-415 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKUW95UUN3ME2xMlM5QDVizszN MmDmV2FPT0WU
NCI-H2342 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwNECyOlkh|ryP MWjTRW5ITVJ?
NB69 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwNE[yO|Eh|ryP MX;TRW5ITVJ?
D-247MG Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwNUGxNlIh|ryP M3HnPHNCVkeHUh?=
SCC-4 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7OTWM2OD1zLkW5PFg4KM7:TR?= M4PZeHNCVkeHUh?=
HuH-7 M4DhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TBbGlEPTB;MT62O|I6OyEQvF2= Mn75V2FPT0WU
A388 M4\NVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G5e2lEPTB;MT62PFczPCEQvF2= MkHSV2FPT0WU
Calu-3 M2Wyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;IWmFKSzVyPUGuO|A3QTdizszN MVnTRW5ITVJ?
NCI-H1648 NFvRfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwN{G0NVgh|ryP M1jHbHNCVkeHUh?=
NCI-H2052 NYrTTGVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XqUmlEPTB;MT63NlIxOSEQvF2= MmjZV2FPT0WU
Ramos-2G6-4C10 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwN{O2OVYh|ryP Ml;TV2FPT0WU
DEL NVPqU2hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwN{S2PVIh|ryP NIizfoVUSU6JRWK=
SNU-423 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHoOI5KSzVyPUGuO|gyPTdizszN NXvqT4Z6W0GQR1XS
COR-L23 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwN{m4O|Qh|ryP Ml3lV2FPT0WU
OMC-1 NVntTI9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonNTWM2OD1zLki2NFE3KM7:TR?= MnTCV2FPT0WU
EW-11 NIrHVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofLTWM2OD1zLkm1OlU4KM7:TR?= MWDTRW5ITVJ?
HSC-3 NXHzOFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\DTWM2OD1zLkm2N|Y2KM7:TR?= MkHGV2FPT0WU
MLMA M1rB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwOU[2O|ch|ryP NXPlWGFUW0GQR1XS
RCM-1 NVj6[IQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfBTYxWUUN3ME2yMlAxOzl7IN88US=> M1XmcnNCVkeHUh?=
MFE-280 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni0TWM2OD1{LkCyPFQ5KM7:TR?= NWn2T|E6W0GQR1XS
ES8 M1u5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMkW0O|Eh|ryP NV7qc3VIW0GQR1XS
TE-11 M{TqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH0fIRHUUN3ME2yMlI6PDd|IN88US=> M{H1d3NCVkeHUh?=
HuO-3N1 NFLyR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLxTWM2OD1{LkS4O|gh|ryP MnPWV2FPT0WU
MHH-NB-11 NHj0eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVntfFl6UUN3ME2yMlUyOTV6IN88US=> MlrPV2FPT0WU
TGBC11TKB M{X3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXHTWM2OD1{LkW3OlgyKM7:TR?= NG\qW4JUSU6JRWK=
HOP-92 M{HNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJwNUi3OFMh|ryP MVLTRW5ITVJ?
IGR-1 M{Dybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\1elBKSzVyPUKuOlIxOzVizszN NITlNFJUSU6JRWK=
GOTO M17sXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXGfGVEUUN3ME2yMlY2Ozd5IN88US=> NY\2bId4W0GQR1XS
NCI-H1650 M1X3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD5dmNKSzVyPUKuO|IzOTVizszN MVnTRW5ITVJ?
NCI-H1581 M{WwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ZNmlEPTB;Mj63PVY5OSEQvF2= M4TG[XNCVkeHUh?=
NCI-H2405 NXnoSJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJwOEK3PFIh|ryP M{[1SHNCVkeHUh?=
U-118-MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z6fWlEPTB;Mj65OlQ6OSEQvF2= M4ToU3NCVkeHUh?=
DoTc2-4510 NH;obpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X0WmlEPTB;Mz6wNVQyPyEQvF2= NUniWo9VW0GQR1XS
NCI-H596 NVPQNYF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LQdGlEPTB;Mz6wOFk6PyEQvF2= NV3SeGZ1W0GQR1XS
MPP-89 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LuXGlEPTB;Mz6wOVY3PiEQvF2= M1Pl[HNCVkeHUh?=
GCIY MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLJOGhSUUN3ME2zMlIxPDlzIN88US=> NW\abnJQW0GQR1XS
SW626 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTNwMkS1OFMh|ryP NFLzfpBUSU6JRWK=
OCI-AML2 NVTHVnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHxeIdKSzVyPUOuN|EzPzJizszN M1XYSnNCVkeHUh?=
NBsusSR NIroUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\MZWlEPTB;Mz6zOFk{QCEQvF2= MVTTRW5ITVJ?
AN3-CA NF[5fHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwNESyN|gh|ryP NG\pXJZUSU6JRWK=
EFM-19 M33COWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPe2ZKSzVyPUOuOFg{OzlizszN MVjTRW5ITVJ?
RVH-421 NGHvWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:2TFZ7UUN3ME2zMlU3QDd5IN88US=> NXLXR2J4W0GQR1XS
5637 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmxTWM2OD1|Lk[xNVA{KM7:TR?= MYjTRW5ITVJ?
PANC-08-13 NFrFZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfvTWM2OD1|Lk[zOFczKM7:TR?= MonRV2FPT0WU
H9 NH;iUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHHZo1KSzVyPUOuOlcyPDRizszN MmewV2FPT0WU
KARPAS-299 NYHjOYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwNkezOlEh|ryP NF;aTFdUSU6JRWK=
TE-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnexTWM2OD1|LkewO|A6KM7:TR?= NVW2[FVsW0GQR1XS
NOS-1 NFnKXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwN{m4N|Qh|ryP NInYdJhUSU6JRWK=
HH MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwOEO4Olgh|ryP NWjaeYVFW0GQR1XS
769-P NXv2fmV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvXTWM2OD1|Lki5OVEh|ryP MnzkV2FPT0WU
CHP-212 Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwOUK1OFkh|ryP NYiwOnN3W0GQR1XS
NCI-H82 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILGWGtKSzVyPUOuPVU6OzZizszN MUHTRW5ITVJ?
Mo-T NUTRfXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rvVmlEPTB;ND6wOFMyOiEQvF2= M{DyNXNCVkeHUh?=
BB65-RCC NIq0VVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTRwMESzPVkh|ryP M3XuPHNCVkeHUh?=
SW1990 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln4TWM2OD12LkC1PVA5KM7:TR?= NUG1bnhtW0GQR1XS
LK-2 NF3nZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjsSnRKSzVyPUSuNVEzQTNizszN NULDbnhWW0GQR1XS
ES5 M2LvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRwMUO5PFUh|ryP NED1b3FUSU6JRWK=
JVM-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwMUiyNlIh|ryP MU\TRW5ITVJ?
RPMI-7951 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr2TWM2OD12LkKyOFE{KM7:TR?= MnHTV2FPT0WU
Calu-6 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTRwMke4PFEh|ryP NF[z[25USU6JRWK=
LC-2-ad MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\pS4tNUUN3ME20MlI6PTZ6IN88US=> NX60UodTW0GQR1XS
SW954 NX;Sepo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XEemlEPTB;ND6yPVY3KM7:TR?= NWLpcmRqW0GQR1XS
H-EMC-SS M3HBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjKRmQzUUN3ME20MlMyQDNzIN88US=> MWHTRW5ITVJ?
ES3 NYrsSIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf3TWM2OD12LkO1OFQyKM7:TR?= MWPTRW5ITVJ?
no-11 NUPLWI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTRwM{W1OVQh|ryP MnvEV2FPT0WU
LAN-6 M4jG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi5NZAyUUN3ME20MlQ2OTh7IN88US=> NVjLSFRZW0GQR1XS
FTC-133 M2iwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTRwNUO5OUDPxE1? NYPDXVB2W0GQR1XS
8505C NWPFU4JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TFfWlEPTB;ND61OFI{KM7:TR?= NF;udYhUSU6JRWK=
SW620 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvOTWM2OD12LkW3NFU4KM7:TR?= M1LKfHNCVkeHUh?=
BCPAP Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljHTWM2OD12Lk[zOFgyKM7:TR?= MUjTRW5ITVJ?
SK-LU-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwNk[wPFkh|ryP NIPOdG9USU6JRWK=
NCI-H1623 NH\nZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjzTWM2OD12LkewNlI5KM7:TR?= MXvTRW5ITVJ?
C2BBe1 NF:4OWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\xWXdUUUN3ME20Mlc1ODB6IN88US=> M131d3NCVkeHUh?=
GP5d MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\JcmlEPTB;ND63PFM5QCEQvF2= M4fGOnNCVkeHUh?=
NB6 NE[x[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Lmb2lEPTB;ND64OlIxPCEQvF2= NEnWXGlUSU6JRWK=
MDA-MB-157 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTLNodKSzVyPUSuPFg4PiEQvF2= Ml7FV2FPT0WU
UMC-11 NG\hWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDheVBKSzVyPUSuPFg6PjRizszN Mkf2V2FPT0WU
HCC1419 NUjheI9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLCTWM2OD12LkmwNFY{KM7:TR?= NFfHVopUSU6JRWK=
NCI-H2029 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXqN3d1UUN3ME20Mlk1OTh3IN88US=> M3ztSnNCVkeHUh?=
LXF-289 M1HFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSx[Ys{UUN3ME21MlA{PzF7IN88US=> NV7seIljW0GQR1XS
KINGS-1 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfCRWlRUUN3ME21MlA4PzR2IN88US=> MkK4V2FPT0WU
HD-MY-Z NHHlXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXuTWM2OD13LkKzPVY6KM7:TR?= NV6zZWtbW0GQR1XS
ESS-1 NGDYO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i3dmlEPTB;NT6yOVU6PyEQvF2= MljJV2FPT0WU
GI-1 NVXlUo85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTnZphCUUN3ME21MlI4QTJ4IN88US=> NWLnUFRFW0GQR1XS
RPMI-2650 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTVwM{[xOkDPxE1? M3v6UnNCVkeHUh?=
IA-LM NVm0W|Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrmO|ZvUUN3ME21MlM6QDdzIN88US=> NXuwUmlOW0GQR1XS
KP-4 NYP2VIJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXQW5lMUUN3ME21MlQ3OzN2IN88US=> NYrzcIpZW0GQR1XS
G-402 M{HWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:ycoZtUUN3ME21MlUyQDZ3IN88US=> M{PWdnNCVkeHUh?=
OS-RC-2 NX7ueWcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ThUmlEPTB;NT61NlYxPCEQvF2= NGSyZmVUSU6JRWK=
NCI-H1155 NILLOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LYUmlEPTB;NT61OFk2PSEQvF2= MWXTRW5ITVJ?
OE19 NY\ET2tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XuVWlEPTB;NT62PFYzPCEQvF2= NITSWotUSU6JRWK=
U-2-OS NEHMU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfjblZQUUN3ME21Mlg6ODF|IN88US=> NHLERW5USU6JRWK=
SCC-15 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwOUO2OlIh|ryP M1jmWXNCVkeHUh?=
NCI-H630 NEHvc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTVwOUm0NFQh|ryP MUjTRW5ITVJ?
PFSK-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;vRmlEPTB;Nj6wOVI2QSEQvF2= NXPBN4JjW0GQR1XS
NCI-H1770 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDyOllKSzVyPU[uNlA5PzRizszN NHfsOYpUSU6JRWK=
SK-MEL-3 M{\tVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HVdWlEPTB;Nj60NlkyPSEQvF2= NUfqdGV[W0GQR1XS
LB1047-RCC NITGcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK1TWM2OD14LkS3OlI2KM7:TR?= M3PFNXNCVkeHUh?=
NCI-H446 M13rNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3zSohZUUN3ME22MlYzQTJ3IN88US=> M33N[XNCVkeHUh?=
SW780 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XJ[GlEPTB;Nj63NFE5PSEQvF2= NWS5ZnliW0GQR1XS
NEC8 NUPFRVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfHTWM2OD14Lke2OlMh|ryP M{jRe3NCVkeHUh?=
NOMO-1 NX3x[ZFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW1TWM2OD14Lke4NVEyKM7:TR?= MX\TRW5ITVJ?
COLO-668 NUPSXo52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jXWmlEPTB;Nj64OFM5PyEQvF2= M2LWRXNCVkeHUh?=
MC116 NWH4UlNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnYTWM2OD14LkmzPFk4KM7:TR?= MVfTRW5ITVJ?
HCC1937 NHfDT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCxTWM2OD14Lkm5NlUyKM7:TR?= MXPTRW5ITVJ?
NCI-N87 NU[0XWp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHUZ|ZtUUN3ME23MlE6Ojl|IN88US=> NGLlS2tUSU6JRWK=
COLO-320-HSR M{DuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHpV3VVUUN3ME23MlIzPzN6IN88US=> MWPTRW5ITVJ?
HCC1806 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3STWM2OD15LkK2NFQ1KM7:TR?= NWDBPY9NW0GQR1XS
OVCAR-3 NEHae|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj6TWM2OD15LkOzNFM5KM7:TR?= NH[wXopUSU6JRWK=
NUGC-3 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rOcGlEPTB;Nz6zPVY6PCEQvF2= M4XEZXNCVkeHUh?=
SW1783 NWHEZZE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\5c4N7UUN3ME23MlQ{OTd3IN88US=> NIXNdmNUSU6JRWK=
GCT NYjKd41ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHiPYRKSzVyPUeuOVY6ODZizszN MX7TRW5ITVJ?
NCI-H2126 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXPOnVKSzVyPUeuO|M3OjVizszN Mmr3V2FPT0WU
MEL-HO NX\lVok4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHvTWM2OD15Lke3NFU1KM7:TR?= MXrTRW5ITVJ?
CAPAN-1 NF\ifJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTdwN{ezOVch|ryP M2nseXNCVkeHUh?=
SW756 MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTdwN{izN|Mh|ryP MmfpV2FPT0WU
SKG-IIIa MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfVVVF5UUN3ME23MlgyQDl{IN88US=> NHzMSVhUSU6JRWK=
HCE-T NIj5ToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmroTWM2OD15Lki3O|g{KM7:TR?= NYXVbFdTW0GQR1XS
Ca-Ski M1ixUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTdwOUmzPFMh|ryP MU\TRW5ITVJ?
COLO-684 NXf1OoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPmWnU4UUN3ME24MlAyQDF6IN88US=> MWnTRW5ITVJ?
KYSE-70 NEHRUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PCcGlEPTB;OD6wO|czQSEQvF2= MXTTRW5ITVJ?
TI-73 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4njfWlEPTB;OD6yOVg2OSEQvF2= MVfTRW5ITVJ?
BT-20 NHXyeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTpTWM2OD16LkK2NFUzKM7:TR?= MkTRV2FPT0WU
MHH-ES-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHDTWM2OD16LkWxPFM1KM7:TR?= MmrOV2FPT0WU
TE-12 NXLib2x{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULKUFhYUUN3ME24MlU6QTNzIN88US=> MnnUV2FPT0WU
YH-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCwTWM2OD16Lk[xNFA5KM7:TR?= NVHLNmJjW0GQR1XS
SF126 NGHVeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfQOIVXUUN3ME24Mlg{QDZ3IN88US=> MY\TRW5ITVJ?
J82 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRThwOUCwN|gh|ryP MX3TRW5ITVJ?
RCC10RGB MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRThwOUm1OlEh|ryP NIq4OXVUSU6JRWK=
SK-UT-1 NVuwdVJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nKWWlEPTB;OT6wOFk1PSEQvF2= MkP5V2FPT0WU
LB2241-RCC MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi2bo1KSzVyPUmuNVkyOzdizszN NIjhRYtUSU6JRWK=
LB996-RCC MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHWSm1KSzVyPUmuNVk5QSEQvF2= MnnMV2FPT0WU
EPLC-272H MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4riOGlEPTB;OT6zO|Y2PyEQvF2= MYjTRW5ITVJ?
CTV-1 NIHOdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTlwNU[1N|Ih|ryP M{DnW3NCVkeHUh?=
HSC-2 NVS1OXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjEV3gzUUN3ME25MlU4PTVizszN Ml;VV2FPT0WU
SK-MEL-28 NVLLfZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X2RmlEPTB;OT62NVg6OyEQvF2= MmXBV2FPT0WU
MMAC-SF MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTlwNki3OUDPxE1? NX3RTpc4W0GQR1XS
CP50-MEL-B MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHUd2hwUUN3ME25Mlc2Pzh{IN88US=> M1\s[nNCVkeHUh?=
HT-1080 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T1N2lEPTB;OT63O|c{QSEQvF2= MnjQV2FPT0WU
HEC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;tTWM2OD1zMD6zN|UzKM7:TR?= NIn0VINUSU6JRWK=
AGS M{nZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrVdZZ3UUN3ME2xNE4{PzRizszN NXPTXXdNW0GQR1XS
GAMG MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFyLkWxOlIh|ryP MXXTRW5ITVJ?
SW48 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFyLkWxPFkh|ryP M3LpeXNCVkeHUh?=
U031 NX33O|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjjZnp{UUN3ME2xNE42QTB6IN88US=> M1X2VHNCVkeHUh?=
OVCAR-5 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPxO3l3UUN3ME2xNE43PDJ7IN88US=> M1jtfHNCVkeHUh?=
SF295 M2jncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvjW3BKSzVyPUGwMlY4ODRizszN NUe5WG9qW0GQR1XS
BHT-101 M4fqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFyLkexO|ch|ryP NV3DWFY1W0GQR1XS
VMRC-RCZ NIXpT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOweYJtUUN3ME2xNU4{OjBzIN88US=> NXTsNJVLW0GQR1XS
ACHN MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTpTWM2OD1zMT60NlEyKM7:TR?= MXTTRW5ITVJ?
NCI-H526 NEPlOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPE[m5KSzVyPUGxMlUxPDNizszN NE[1UppUSU6JRWK=
MN-60 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn36TWM2OD1zMT61N|kh|ryP MXPTRW5ITVJ?
NCI-H2291 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFzLkW0OlYh|ryP NF;3emhUSU6JRWK=
SCC-25 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LoWWlEPTB;MUGuO|U2PiEQvF2= M2LZXXNCVkeHUh?=
SK-MEL-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFzLke2N|ch|ryP M{jVR3NCVkeHUh?=
SN12C M3u2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFzLkmzOVUh|ryP M3XIS3NCVkeHUh?=
NCI-H69 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[0ZmlEPTB;MUKuOFI{PCEQvF2= NHfINnhUSU6JRWK=
ME-180 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEizWHpKSzVyPUGyMlcxPTRizszN NVHnTY1OW0GQR1XS
MC-IXC NE\5No5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD0TWM2OD1zMj63OVE5KM7:TR?= MkHFV2FPT0WU
NCI-H2347 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GzZmlEPTB;MUKuO|YyPCEQvF2= M1n4VnNCVkeHUh?=
M059J MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ZTWM2OD1zMj63O|I4KM7:TR?= MYjTRW5ITVJ?
A2058 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzxXldKSzVyPUGyMlg3QDFizszN M4rvT3NCVkeHUh?=
VA-ES-BJ Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\BemlEPTB;MUKuPFc5PSEQvF2= M{L3[nNCVkeHUh?=
Ca9-22 M3P3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF{Lkm0OVEh|ryP NUD4cmVyW0GQR1XS
KNS-42 M2DESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF{Lkm5PFQh|ryP NVnvc4ZlW0GQR1XS
LoVo MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXETWM2OD1zMz6yN|E{KM7:TR?= NYnVOW5RW0GQR1XS
AM-38 NHGxUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K5NmlEPTB;MUOuNlU3PiEQvF2= MonMV2FPT0WU
NB5 M2PuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD0[lZCUUN3ME2xN{4{PzV{IN88US=> NUm3Znd[W0GQR1XS
L-363 MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF|LkSwN|Mh|ryP MX7TRW5ITVJ?
SK-MEL-30 M4HZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CxRmlEPTB;MUSuNFY1PSEQvF2= MnzFV2FPT0WU
NCI-H1563 NVzGe5Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\ETWM2OD1zND62NFM6KM7:TR?= NXTqeYFoW0GQR1XS
NCI-H2228 M{PM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L6VWlEPTB;MUSuOlA4PyEQvF2= NHT4T4xUSU6JRWK=
MFM-223 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe3PFNKSzVyPUG1MlE5OTNizszN NWTS[4hmW0GQR1XS
LB831-BLC MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK1TWM2OD1zNT6yO|Y4KM7:TR?= NX7Nc3RDW0GQR1XS
SW872 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TiOWlEPTB;MUWuN|A5PiEQvF2= NVvZZoNPW0GQR1XS
NCI-H522 NWTB[3hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfqRYRKSzVyPUG1MlM{ODZizszN M{ToSnNCVkeHUh?=
EW-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHa[GtmUUN3ME2xOU42PDZ{IN88US=> MYXTRW5ITVJ?
HN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj2dHJrUUN3ME2xOU42QTR{IN88US=> NU\zfVh6W0GQR1XS
SW837 NX6xcXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXSe2FKSzVyPUG1Mlc5PDdizszN MV3TRW5ITVJ?
SCC-9 NIPURplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3LkixNVQh|ryP M33WeXNCVkeHUh?=
MKN7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XCXGlEPTB;MUWuPVc{OiEQvF2= NUHzVZh[W0GQR1XS
KYSE-410 M4G0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\IOmFKSzVyPUG2MlU6OSEQvF2= NIS3WVRUSU6JRWK=
SK-N-DZ NG[2WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nxSGlEPTB;MU[uOlEyPiEQvF2= MnPlV2FPT0WU
COR-L105 NHfCWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWwcnk5UUN3ME2xOk43PTJ6IN88US=> NFfrVXZUSU6JRWK=
LB2518-MEL Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnxV3dKSzVyPUG2Mlg{QDlizszN Mk\JV2FPT0WU
OVCAR-4 M4fvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fQd2lEPTB;MU[uPFg3OiEQvF2= NIfnOVNUSU6JRWK=
TK10 NVvnOFhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTWTWM2OD1zNj65OFc{KM7:TR?= NV3URnp3W0GQR1XS
KNS-62 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly3TWM2OD1zNj65O|c4KM7:TR?= NGDZ[GhUSU6JRWK=
RPMI-8866 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzaZXBKSzVyPUG3MlE4OzJizszN NEfHdpRUSU6JRWK=
HuP-T4 NEn2ZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnkTWM2OD1zNz6yOFk2KM7:TR?= Mo\tV2FPT0WU
CGTH-W-1 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj5V2J5UUN3ME2xO{42OjF7IN88US=> NUPSRW9{W0GQR1XS
T-24 NELZcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OwOmlEPTB;MUeuOVM1PyEQvF2= NFXTO3VUSU6JRWK=
HT-3 NXnldVY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF5LkW5NVQh|ryP Mln2V2FPT0WU
KS-1 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nEPWlEPTB;MUeuOlc{KM7:TR?= NWC3boZHW0GQR1XS
NCI-H1792 M{fyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF5Lke5PEDPxE1? NVz6RpdLW0GQR1XS
ABC-1 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLWSnFKSzVyPUG3MlgyPDFizszN NITWe5lUSU6JRWK=
BPH-1 NVnwenprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF6LkG2PFUh|ryP NH;DWodUSU6JRWK=
A431 NXzFU2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\UTWM2OD1zOD60NVI4KM7:TR?= MlPUV2FPT0WU
T98G MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;DTWM2OD1zOD61NVU4KM7:TR?= NF3qOoJUSU6JRWK=
BHY MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF6Lki2PUDPxE1? NHnH[VdUSU6JRWK=
Capan-2 NE\sTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnlTWM2OD1zOD65NFc5KM7:TR?= NH[wWpJUSU6JRWK=
MDA-MB-175-VII MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLGTWM2OD1zOD65NlA6KM7:TR?= NWG2Oo97W0GQR1XS
CAL-27 NEnYfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjl[lFKSzVyPUG5MlA1QDdizszN M2LSNHNCVkeHUh?=
AsPC-1 NV\1V2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWCy[4hTUUN3ME2xPU45PjV5IN88US=> MlvCV2FPT0WU
KU812 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr5TWM2OD1zOT65OVc{KM7:TR?= NHTlZmxUSU6JRWK=
NCI-H441 M1TMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJyLkCwNUDPxE1? NY\HOnlRW0GQR1XS
Mewo MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\WUGlEPTB;MkCuNVI5QCEQvF2= NV\pNoVtW0GQR1XS
SK-MEL-24 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTvTWM2OD1{MD6xOFc4KM7:TR?= NHnrZWpUSU6JRWK=
NCI-H727 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXDPHp[UUN3ME2yNE4zPzB2IN88US=> MXjTRW5ITVJ?
EKVX NGOxdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHzTWM2OD1{MD62NFYh|ryP NG\MdohUSU6JRWK=
RT-112 NWnBZpF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy0bJVIUUN3ME2yNE43OTJ{IN88US=> M4LYWnNCVkeHUh?=
CAMA-1 NX\XPJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PjS2lEPTB;MkCuPVgxOyEQvF2= NILNclNUSU6JRWK=
SW900 NW\uUGxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDEZmtKSzVyPUKxMlAyPDlizszN NE\wT5JUSU6JRWK=
NCI-H23 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHLOnpNUUN3ME2yNU4yOjd5IN88US=> NYTVbJgxW0GQR1XS
SK-PN-DW MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HpeWlEPTB;MkGuNVY1QSEQvF2= M4jHdnNCVkeHUh?=
BB30-HNC M3y5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjpSnpKSzVyPUKxMlI4PDVizszN NWXNd4doW0GQR1XS
VM-CUB-1 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDk[402UUN3ME2yNU4{PTN4IN88US=> MX3TRW5ITVJ?
IST-MEL1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJzLkO2PVIh|ryP NIWyWI1USU6JRWK=
CTB-1 NXT3NFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rr[GlEPTB;MkGuOFc2PSEQvF2= MkPaV2FPT0WU
LCLC-103H MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX32NVBvUUN3ME2yNk4yPTh{IN88US=> MnnMV2FPT0WU
PANC-03-27 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPzTWM2OD1{Mj61NVY6KM7:TR?= M4HLfHNCVkeHUh?=
HTC-C3 M4XpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ{LkW1OVUh|ryP NYrzblNwW0GQR1XS
TE-8 NIroZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJ|LkK1OlUh|ryP M4HDRXNCVkeHUh?=
NCI-H292 NFT1UZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4WmlEPTB;MkWuN|U{PiEQvF2= Mo\lV2FPT0WU
COLO-680N MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ3Lk[zNlkh|ryP NHXJeGpUSU6JRWK=
KYSE-520 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJ3Lk[0OEDPxE1? M136b3NCVkeHUh?=
NB10 M1\jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknUTWM2OD1{Nj6zNVE4KM7:TR?= NIC0NGRUSU6JRWK=
NCI-H661 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrYSWtKSzVyPUK2MlQ4OTNizszN NHTJfpBUSU6JRWK=
GMS-10 NHHOTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\BPW1KSzVyPUK2Mlg3OzhizszN MXjTRW5ITVJ?
NCI-H2122 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76bFRJUUN3ME2yOk46QTl6IN88US=> NHjGTVFUSU6JRWK=
OVCAR-8 NXXjRZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPMT|BuUUN3ME2yO{4xPjN6IN88US=> MUXTRW5ITVJ?
DJM-1 NFT5cFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzvTWM2OD1{Nz6xOFU1KM7:TR?= M3HTcHNCVkeHUh?=
UACC-893 M{nZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;EdWlEPTB;MkeuPVg4QCEQvF2= NHXNR|NUSU6JRWK=
C8166 M{DscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTYbVZKSzVyPUK4MlY6OzhizszN NEH6WHBUSU6JRWK=
NCI-H1693 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3YXHBMUUN3ME2yPE43QTd3IN88US=> MWDTRW5ITVJ?
TYK-nu NYrYU4dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNyLkCzOFUh|ryP MoO1V2FPT0WU
SW1710 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD1|MD6xNlYh|ryP NFO2[YhUSU6JRWK=
A375 M3racmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrqcWFKSzVyPUOwMlMzPDNizszN M3njTXNCVkeHUh?=
HMV-II NXHHN3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HZPGlEPTB;M{GuN|U6OiEQvF2= NFHke4RUSU6JRWK=
NCI-H2087 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNzLk[zOVIh|ryP NX3ON5VVW0GQR1XS
CAL-54 M3vLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKyTWM2OD1|MT63NlQyKM7:TR?= NVTucXhlW0GQR1XS
HCC70 NUfWVIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnKdY5pUUN3ME2zNk4yOzh5IN88US=> MX7TRW5ITVJ?
ES1 NFvQenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN{LkOwOlIh|ryP NVTMOZppW0GQR1XS
NCI-H1355 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf5XnNFUUN3ME2zN{4zODRizszN M4[yPXNCVkeHUh?=
CFPAC-1 M1O1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPweXRKSzVyPUOzMlI{OzJizszN NXSycXk1W0GQR1XS
MKN28 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vrSmlEPTB;M{OuN|gxQSEQvF2= M4fMWHNCVkeHUh?=
HDLM-2 NWTyOFJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\kTWM2OD1|Mz62PVMyKM7:TR?= NFvXTmpUSU6JRWK=
PANC-10-05 NWTFUphYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PyPGlEPTB;M{SuNVAyPCEQvF2= NFvmPIZUSU6JRWK=
SAS NEPzUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fTcWlEPTB;M{SuOFU3PSEQvF2= MUfTRW5ITVJ?
HCC1395 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XsOmlEPTB;M{SuO|E5PiEQvF2= M3rFbnNCVkeHUh?=
8305C NEXWRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN3Lki0NVUh|ryP NUHBfZlwW0GQR1XS
KM12 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTEfGtKSzVyPUO2Mlc2PDdizszN NHHuOYhUSU6JRWK=
SW1116 NHPZPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:4ZWpKSzVyPUO3MlU6QTJizszN NHrqWFBUSU6JRWK=
SK-MEL-1 NHLkb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTN6LkOzPFkh|ryP MWLTRW5ITVJ?
HCC2218 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTN6Lk[1NVkh|ryP MYXTRW5ITVJ?
T84 M2\WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G5RmlEPTB;M{iuO|QxQSEQvF2= M33pR3NCVkeHUh?=
ETK-1 NHK0dpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHSboZKSzVyPUO5MlAzOiEQvF2= M{C5VHNCVkeHUh?=
COLO-800 NGnp[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTN7LkO4Olgh|ryP M1fpTXNCVkeHUh?=
CAL-12T M{\UWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXEZnhKSzVyPUO5MlUzQDFizszN MV\TRW5ITVJ?
ACN NHXaUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SyOmlEPTB;NECuOFkyOSEQvF2= M2DCTXNCVkeHUh?=
SJSA-1 M1vFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nXcGlEPTB;NEGuNVU6PiEQvF2= MWfTRW5ITVJ?
PSN1 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zqRmlEPTB;NEGuNVc1QSEQvF2= NITkOZRUSU6JRWK=
D-566MG NHTWeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ocnBKSzVyPUSxMlIxQDZizszN MlLZV2FPT0WU
EGI-1 NI\Ve3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPESXFKUUN3ME20Nk41OjhizszN NW\jPIJsW0GQR1XS
A204 M4\MR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvKe5BKSzVyPUSyMlY{QDhizszN NVLuO3pCW0GQR1XS
Saos-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR{LkizOlkh|ryP MVzTRW5ITVJ?
SNU-C2B NHPMZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITSO|NKSzVyPUSzMlY5PzhizszN MnTEV2FPT0WU
HLE NYrzc3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITWPIpKSzVyPUS0MlA5PTZizszN NULiW3hNW0GQR1XS
SW1463 NIS0PVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR2Lkm5O|Eh|ryP MkLSV2FPT0WU
DSH1 MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OwNGlEPTB;NEWuNFA{OyEQvF2= MYHTRW5ITVJ?
MCF7 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm1TWM2OD12NT61NFUyKM7:TR?= NGfC[FVUSU6JRWK=
K5 NFvaSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fVbWlEPTB;NEWuPVQxPSEQvF2= MUXTRW5ITVJ?
NCI-H358 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTR5LkKxOUDPxE1? Ml3FV2FPT0WU
NCI-H2030 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fCS2lEPTB;NEeuNlM4PCEQvF2= M3HabXNCVkeHUh?=
SW948 NV;sR5prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LBZWlEPTB;NEeuOFY1KM7:TR?= NF;SUXVUSU6JRWK=
BALL-1 M{CyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3excmlEPTB;NEeuOlE3QCEQvF2= NWKyNIdRW0GQR1XS
TE-9 NX;Ge4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7IfJI{UUN3ME20O{46PThzIN88US=> MYXTRW5ITVJ?
SK-N-FI MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTR6LkCzOVgh|ryP NIDUTXJUSU6JRWK=
KALS-1 NGPXZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj0dFZPUUN3ME20PE4yOjh7IN88US=> M3;HWXNCVkeHUh?=
HO-1-N-1 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTR6Lke0OFUh|ryP NHv0VldUSU6JRWK=
NCI-H2452 M2L0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR7LkGxOVIh|ryP Mkj2V2FPT0WU
OC-314 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jQNGlEPTB;NEmuOlg{PCEQvF2= MVPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
臨床試験 ABT-263 is currently in Phase II clinical trial for the treatments of chronic lymphocytic leukemia.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

細胞アッセイ:

[1]

細胞株 SCLC cell lines
濃度 0-1 μM
反応時間 48 hours
実験の流れ

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

動物実験:

[1]

動物モデル C.B.-17 scid-bg or C.B.-17 scid mice
製剤 Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
投薬量 100 mg/kg/d
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download ABT-263 (Navitoclax) SDF
分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

カスタマーフィードバック (13)


Click to enlarge
Rating
Source , , J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines KP cells & A549 cells
Concentrations 300、500 nM
Incubation Time 96 h
Results KP mouse and A549 cells treated with a combination of ATN-224 and ABT-263 showed an increase in cell death compared with cells treated with ATN-224 alone.

Click to enlarge
Rating
Source , , Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines NSC & Mcl-1 cells
Concentrations
Incubation Time 5 d
Results As seen with ABT-263, cells were largely resistant to compound alone but were extremely sensitive to combination with Mcl-1 silencing. In summary, the Bcl-xL inhibitors ABT-263 and WEHI-539 have an additive effect with Mcl-1 knockdown to reduce cell viabi眏Ỵ眐㠞眎膉癠 

Click to enlarge
Rating
Source Clin Cancer Res , 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescence polarization assay
Cell Lines
Concentrations 0.1-10 μmol/L
Incubation Time 4-12 h
Results To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay.There are two main drug-binding sites on HSA: site 1 on subdomain IIA and site 2 on subdomain IIIA.Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-III A than did ABT-737 (Fig. A). Whereas ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC50 of 145 μmol/L (positive control phenylbutazone: 49 μmol/L; ref. 18; Fig. B) . These data show that ABT-263 has a higher albumin-binding capacity than does ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescein-dextran release assay/western blot
Cell Lines CLL cells
Concentrations 0-5 μmol/L
Incubation Time 1-2.5 h
Results One possible explanation for the reduced potency of ABT-263 compared with ABT-737 could be due to the former being inherently less potent. To investigate this possibility we compared their activities in a model biochemical system, using liposomes loaded with fluorescein-conjugated 10 kD dextran.The BCL-XL-mediated inhibition of liposome permeabilization was reversed in an a lmost identical concentration-dependent manner by both ABT-263 and ABT-737 (Fig. A). These results showed that both ABT-263 and ABT-737 targe t antiapoptotic BCL-XL with similar efficiency in this model liposome system containing only BCL2 family members but devoid of extraneous proteins. Another explanation for the lower potency of ABT-263 could be a lower plasma membrane permeability.we investigated the potential of ABT-737 and ABT-263 to induce cytochromec release from permeabilized CLL cells(Fig. B). ABT-737 was clearly more potentin inducing cytochrome c release from permeabilized cells.Taken together these results indicate that the reduced potential of ABT-263 to induce apoptosis cannot be explained solely by either differential plasma membrane permeability or by a lower potency of ABT-263 compared with ABT-737 to inhibit antiapoptotic BCL2 family members.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Mitochondrial membrane potential assay/Immunoprecipitation/electron microscopy/apoptosis assays
Cell Lines CLL cells/murine embryonic fibroblasts
Concentrations 10-100 nmol/L/0.3-30 μmol/L
Incubation Time 2-48 h
Results To gain in sight into the mechanism of ABT-263-induced cell death, we asked whether ABT-263 induced activation of apoptotic signaling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was a gain less potent than ABT-737 ( Fig.A).To investigate the activity of both compounds at the level of BCL2 inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263.BAK was shown to be associated with BCL2 (Fig. B). ABT-737 (10 or 100 nmol/L) efficiently d isplaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nmol /L) were required to induce release of BAK (Fig. B).ABT-263 (100 nmol/L) induced similar ultrastructural changes to ABT-737 (10 nmol/L), including condensed chromatin, rupture of the outer mitochondrial membrane, and loss of mitochondrial matrix d ensity (Fig. C).Finally, ABT-263-induced apoptosis was compl et ely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. D), suggesting that ABT-263, like ABT-737 is a specific inhibitor of BCL2 proteins.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results In our study we identify two factors that affect the efficacy of the ABT-263: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-263 that we observed in whole blood as compared with standard cell culture (Fig. B).We also describe that the ABT-263 is extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. D)

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results We compared the in vitro efficacy of two very closely related BCL2 antagon ists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was∼4-fold more potent.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Hoechst staining/western blot
Cell Lines LH86 cells/Huh7 cells
Concentrations 0–20 μM
Incubation Time 24 h
Results The higher dose of ABT-263 (10–20 μM) treatment for 24 h induced significant DNA fragmentation and caspase 9 or 3 cleavage activation in HCC cells, whereas lower concentrations of ABT-263 (0–2.5 μM) had no apoptotic toxicity to HCC cells. These results suggest that HCC cells are relatively resistant to low doses of ABT-263.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining/Apoptosis assays
Cell Lines LH86 cells
Concentrations 1 μM
Incubation Time 1-6 h
Results As shown in Figure A, the combination treatment of HCC cells with ABT-263 (1 μM) and YM-155 (1μM) for up to 6 h has no effects on the expressions of either anti-apoptotic protein Bcl-xL or pro-apoptotic proteins including Bad, Bak, and Bax. However, as expected, the presence of YM-155 significantly decreased survivin protein expression (Figure B, left third lane). Co-treatment of cells with ABT-263 (1 μM) and YM-155 (1μM) induced an even greater decrease in survivin protein expression (Figure B, right two lanes) than that of YM-155 itself did. However, we indeed observed that ABT-263 single treatment for 3 h resulted in survivin increase (Figure B). To further determine survivin inhibition plays a critical role in sensitizing ABT-263 to induce apoptosis in HCC cells, we down-regulated survivin expression in HCC cells by siRNA duplexes targeted against human survivin mRNA, and then examined the expression of survivin by Western blotting (Figure C) and apoptotic events after ABT-263 treatments. The results demonstrated that ABT-263 induced significant apoptosis in the survivin siRNA-transfected cells, but not in siRNA Random-transfected (control) cells (Figure D, E, and F).

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining
Cell Lines LH86 cells
Concentrations 1-2.5 μM
Incubation Time 1-24 h
Results Treatment of cells with ABT-263 (1-2.5 μM) for 1 h could result in the increase of phosphorylated ERK (p-ERK) but not ERK (Figure A). On the other hand, as shown in Figure B, ABT-263 (1 μM) administration could result in survivin expression increase. Thus, in an attempt to know if ERK-survivin activation could protect cells against ABT-263 toxicity, cells were untreated or treated with ABT-263 (1 μM), PD98059 (50 μM), or pre-treated with PD98059 (50 μM) followed by ABT-263 (1 μM). As shown in Figure C and D, blocking ERK activation with specific inhibitor PD98059 enhanced ABT-263-indcued apoptosis in HCC cells. To further determine ERK anti-apoptotic effects on ABT-263 treated HCC cells, we knocked down ERK expression through siRNA mediated gene silencing (Figure E) and then administrated ABT-263. Similar results revealed that ERK depletion sensitized ABT-263-induced apoptosis (Figure F). These results suggest the activation of ERK-survivin may render cells to be resistant to low dose ABT-263-induced apoptosis.

Click to enlarge
Rating
Source Biochem Biophys Res Commun, 2011, 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines Arf -null p185+ cells/ p185+ Arf-/- cells
Concentrations 0-1000nM
Incubation Time 24 h
Results As the navitoclax dose increased the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased and there was a corresponding increase in MCL-1 protein associated with BIM (Fig. B). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-XL and suggests that the liberated BIM could then interact with MCL-1 (Fig. B). As the navitoclax was increased we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment (Fig. E&F).

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines OP-1 Ph+ B-ALL cells/TOM1 Ph+ B-ALL cells/BV173 Ph+CML cells
Concentrations 0-60 nM
Incubation Time 24 h
Results As navitoclax was increased in the cultures we observed a potentiation of the TKIs to induce apoptosis. These data indicate that like our bservations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph+ cell lines can also lead to enhanced activity. While MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may effect targets other than MCL-1 leading to cell death. These data suggest that combining TKIs and navitoclax may be effective in treating human Ph+ leukemia.

文献中の引用 (36)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737は、Bcl-xL、Bcl-2とBcl-wのBH3模倣の阻害剤で、EC50 がそれぞれ78.7 nM、30.3 nM 、197.8 nMになる。

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は Bcl-2 を抑制して、 Kiが0.22 μMになる.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37は、組み換え型Bcl-2(Bcl-xLとMcl-1)への新しい非ペプチド阻害剤で、Ki がそれぞれ 0.29 μM、1.11 μM、0.26 μMです。

  • Sabutoclax

    Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT-101は、反アポトーシスのBcl-2 の強力な阻害剤であることを知られて、模倣のBH3家族です。

最近チェックしたアイテム

Tags: ABT-263 (Navitoclax)を買う | ABT-263 (Navitoclax)供給者 | ABT-263 (Navitoclax)を購入する | ABT-263 (Navitoclax)費用 | ABT-263 (Navitoclax)生産者 | オーダーABT-263 (Navitoclax) | ABT-263 (Navitoclax)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ